Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital's target price points to a potential upside of 484.11% from the company's current price.

HUMA has been the topic of several other reports. BTIG Research reissued a "buy" rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Humacyte in a research report on Wednesday, November 13th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a "neutral" rating in a research report on Friday, October 18th. Benchmark reaffirmed a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a "strong-buy" rating in a research note on Monday, September 9th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $13.00.

Humacyte Price Performance

Shares of NASDAQ:HUMA traded down $0.21 on Thursday, hitting $4.28. The stock had a trading volume of 3,606,094 shares, compared to its average volume of 2,419,976. The firm's 50 day moving average price is $5.31 and its 200-day moving average price is $6.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. Humacyte has a twelve month low of $2.43 and a twelve month high of $9.97. The company has a market capitalization of $538.68 million, a price-to-earnings ratio of -3.35 and a beta of 1.47.

Insider Buying and Selling

In other news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares of the company's stock, valued at $217,490.40. This represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company's stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,584,153 shares of company stock valued at $13,476,796. 11.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company's stock worth $12,501,000 after buying an additional 896,415 shares during the last quarter. Virtu Financial LLC acquired a new stake in Humacyte in the 1st quarter worth about $197,000. ARS Investment Partners LLC acquired a new stake in shares of Humacyte during the 2nd quarter worth $559,000. Bank of New York Mellon Corp lifted its holdings in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company's stock worth $1,219,000 after acquiring an additional 97,931 shares during the period. Finally, Principal Financial Group Inc. bought a new position in shares of Humacyte in the 2nd quarter valued at $83,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.